Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inogen (INGN – Research Report) and Galectin Therapeutics (GALT – Research Report).
Inogen (INGN)
In a report released today, Michael Matson from Needham maintained a Hold rating on Inogen. The company’s shares closed last Tuesday at $7.21.
According to TipRanks.com, Matson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inogen.
See Insiders’ Hot Stocks on TipRanks >>
Galectin Therapeutics (GALT)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Galectin Therapeutics, with a price target of $11.00. The company’s shares closed last Tuesday at $3.83.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Currently, the analyst consensus on Galectin Therapeutics is a Moderate Buy with an average price target of $11.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INGN:
